Albert David

Which are the latest news on Albert David?

Why is Albert David Ltd falling/rising?

As of 05-Sep, the stock price of Albert David Ltd is currently at 858.35, reflecting a decline of 1.05% and a significant drop of 4.53% over the past week. Despite a year-to-date increase of 15.99%, recent trends indicate reduced investor participation and downward pressure on the stock price.

As of 05-Sep, the stock price of Albert David Ltd is falling, currently at 858.35, which reflects a decrease of 9.15 (-1.05%). This decline is part of a broader trend, as the stock has been losing value for the last two days, resulting in a total drop of -1.26% during this period. <BR><BR>In terms of performance relative to the benchmark, the stock has shown a significant decline of -4.53% over the past week, while the Sensex has only decreased by -0.97%. Additionally, the stock's delivery volume has seen a drastic reduction, with a reported volume of 1.16 k on September 3, which is down by -81.18% compared to the 5-day average. This indicates a falling investor participation, which can contribute to downward pressure on the stock price.<BR><BR>Despite the recent decline, the stock has performed well over longer periods, with a year-to-date increase of +15.99% and a 5-year increase of +42.65%. However, the current short-term trends and reduced trading activity suggest that the stock is facing challenges that are leading to its recent price drop.

Who are in the management team of Albert David?

The management team of Albert David includes A K Kothari (Executive Chairman), U. M. Kunte (Managing Director & CEO), Prabhawati Devi Kothari, and Anand Vardhan Kothari as directors, along with several independent directors and A B Chakrabarty as Company Secretary and Compliance Officer.

The management team of Albert David includes the following key individuals:<BR><BR>1. A K Kothari - Executive Chairman<BR>2. U. M. Kunte - Managing Director & CEO<BR>3. Prabhawati Devi Kothari - Director<BR>4. Anand Vardhan Kothari - Director<BR><BR>Additionally, the board features several independent directors:<BR>- Hemal Kampani<BR>- Rajiv Singhi<BR>- Arindam Sarkar<BR>- Shirish Gundopant Belapure<BR>- Monjori Mitra<BR><BR>The company also has A B Chakrabarty serving as the Company Secretary and Compliance Officer. This diverse team brings a range of expertise to the company's leadership.

What does Albert David do?

Albert David Ltd is a micro-cap pharmaceutical company based in Kolkata, specializing in manufacturing and trading pharmaceutical formulations and herbal products. As of June 2026, it reported net sales of 101 Cr and a net profit of 32 Cr, with a market cap of INR 518 Cr.

Overview:<BR>Albert David Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, specializing in the manufacturing and trading of pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs.<BR><BR>History:<BR>Incorporated in 1938 in Kolkata, Albert David Ltd is part of the Kothari Group. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 101 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 32 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 518 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 23.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.56% <BR>Debt Equity: -0.59 <BR>Return on Equity: 5.76% <BR>Price to Book: 1.31 <BR><BR>Contact Details:<BR>Address: D Block 3rd Flr Gillander Hous, Netaji Subhas Road Kolkata West Bengal : 700001 <BR>Tel: 91-33-22302330/2262 8436/8456/ <BR>Email: adidavid@dataone.in <BR>Website: http://www.albertdavidindia.com

Who are the peers of the Albert David?

Peers of Albert David include Shree Ganesh Rem, Bafna Pharma, Kilitch Drugs, and others. Albert David has average management risk and growth, with a 1-year return of 12.39%, lower than Bafna Pharma's 198.53% but higher than Jenburkt Pharma's -4.08%.

Peers: The peers of Albert David are Shree Ganesh Rem, Bafna Pharma., Kilitch Drugs, Valiant Laborato, Jenburkt Pharma, Transchem, Haleos Labs Limi, Medico Remedies, and Infinium Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kilitch Drugs, Jenburkt Pharma, and Medico Remedies, while Average management risk is found at Shree Ganesh Rem, Transchem, Haleos Labs Limi, and Albert David. Below Average management risk is present at Bafna Pharma., Valiant Laborato, and Infinium Pharma. Growth is rated as Good for Kilitch Drugs and Medico Remedies, while Average growth is seen at Shree Ganesh Rem, Bafna Pharma., and the rest. Below Average growth is noted for Valiant Laborato, Albert David, Jenburkt Pharma, Transchem, Haleos Labs Limi, and Infinium Pharma. Capital Structure is Excellent for Shree Ganesh Rem, Albert David, and Jenburkt Pharma, Good for Kilitch Drugs and Medico Remedies, Average for Bafna Pharma., and Below Average for Transchem and Haleos Labs Limi.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bafna Pharma. at 198.53%, while the lowest is Jenburkt Pharma at -4.08%. Albert David's 1-year return is 12.39%, which is higher than Jenburkt Pharma but significantly lower than Bafna Pharma. Additionally, Medico Remedies and Infinium Pharma have negative six-month returns.

How big is Albert David?

As of 31st August, Albert David Ltd has a market capitalization of 518.00 Cr, with recent Net Sales of 364.37 Cr and a Net Profit of 22.57 Cr. Shareholder's Funds are 391.54 Cr and Total Assets amount to 519.13 Cr as of March 2026.

As of 31st August, Albert David Ltd has a market capitalization of 518.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Albert David reported Net Sales of 364.37 Cr and a Net Profit of 22.57 Cr.<BR><BR>The latest reporting period for the balance sheet is March 2026, with Shareholder's Funds amounting to 391.54 Cr and Total Assets of 519.13 Cr.

Should I buy, sell or hold Albert David Ltd?

Are Albert David Ltd latest results good or bad?

Albert David Ltd's latest Q4 FY26 results are concerning, showing a net loss of ₹21.43 crores and a sharp decline in operating margin to 3.20%, despite a year-on-year revenue growth of 14.65%. Overall, the company's financial health appears strained, with significant underperformance compared to the market.

Albert David Ltd's latest results for Q4 FY26 indicate a troubling performance. The company reported a net loss of ₹21.43 crores, which is a significant decline compared to the previous quarter's profit of ₹15.30 crores. This represents a drastic drop of 107.50% quarter-on-quarter. <BR><BR>While the revenue for the quarter was ₹85.86 crores, reflecting a year-on-year growth of 14.65%, it still showed a sequential decline of 4.53% from the previous quarter. The operating margin also fell sharply from 12.03% in Q3 FY26 to just 3.20% in Q4 FY26, indicating severe operational challenges.<BR><BR>The company's overall financial health appears to be under strain, with a market capitalization of ₹408.63 crores and a Mojo Score of 31 out of 100, which suggests significant weaknesses in both fundamental and technical aspects. The stock has underperformed the broader market, declining 20.33% over the past year, while the Sensex fell only 8.21%.<BR><BR>In summary, the latest results for Albert David Ltd are concerning, marked by significant losses, declining margins, and underperformance relative to its peers in the pharmaceutical sector. This situation raises serious questions about the company's operational stability and future prospects.

When is the next results date for Albert David Ltd?

The next results date for Albert David Ltd is 12 May 2026.

The next results date for Albert David Ltd is scheduled for 12 May 2026.

How has been the historical performance of Albert David?

Albert David experienced a decline in financial performance from Mar'24 to Mar'25, with net sales dropping from 362.46 Cr to 345.77 Cr, and profit after tax decreasing from 75.42 Cr to 17.20 Cr, alongside negative cash flow from operating activities. Total assets and liabilities increased, but overall metrics indicate a challenging year.

Answer:<BR>The historical performance of Albert David shows fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Albert David's net sales have varied, with a peak of 362.46 Cr in Mar'24, followed by a decline to 345.77 Cr in Mar'25. The total operating income followed a similar trend, reaching 362.46 Cr in Mar'24 and decreasing to 345.77 Cr in Mar'25. The company's total expenditure, excluding depreciation, increased from 315.58 Cr in Mar'24 to 342.74 Cr in Mar'25. Consequently, the operating profit (PBDIT) saw a significant drop from 104.43 Cr in Mar'24 to 32.61 Cr in Mar'25. Profit before tax also decreased from 97.29 Cr in Mar'24 to 25.23 Cr in Mar'25, leading to a profit after tax of 17.20 Cr in Mar'25, down from 75.42 Cr in Mar'24. The earnings per share (EPS) reflected this decline, falling from 132.08 in Mar'24 to 30.12 in Mar'25. On the balance sheet, total assets rose from 497.99 Cr in Mar'24 to 511.42 Cr in Mar'25, while total liabilities also increased from 497.99 Cr to 511.42 Cr. The cash flow from operating activities turned negative in Mar'25 at -28.00 Cr, contrasting with a positive inflow of 45.00 Cr in Mar'24. Overall, Albert David's financial performance indicates a challenging year in Mar'25 compared to the previous year.

Who are the top shareholders of the Albert David?

The top shareholders of Albert David are Kothari Investment And Industries Private Limited with 41.36%, followed by individual investors at 27.43%. General Insurance Corporation of India is the largest institutional shareholder with 1.61%, while 11 foreign institutional investors hold a combined 1.01%.

The top shareholders of Albert David include Kothari Investment And Industries Private Limited, which holds the largest stake at 41.36%. The company is primarily owned by its promoters, with no pledged promoter holdings reported. Additionally, individual investors collectively hold 27.43% of the shares. Among institutional investors, General Insurance Corporation Of India is the highest public shareholder with a 1.61% stake, while 11 foreign institutional investors (FIIs) hold a combined 1.01%. There is also a small presence of mutual funds, with one scheme holding 0.01%.

Is Albert David technically bullish or bearish?

As of July 7, 2025, Albert David's technical trend has shifted to mildly bearish, with daily indicators showing bearish signals and mixed weekly indicators, reflecting a significant decline in performance year-to-date and over the past year.

As of 7 July 2025, the technical trend for Albert David has changed from sideways to mildly bearish. The current technical stance is bearish, with a mild strength indicated by the daily moving averages showing a bearish signal. The weekly MACD and KST are mildly bullish, but the monthly indicators, including MACD and Bollinger Bands, are mildly bearish, suggesting a mixed outlook. The stock's recent performance shows a significant decline year-to-date and over the past year, further supporting the bearish sentiment. Overall, the combination of daily bearish signals and mixed weekly indicators leads to a bearish stance.

Is Albert David overvalued or undervalued?

As of May 14, 2025, Albert David's valuation has shifted from attractive to risky due to its overvaluation indicated by a high PE ratio of 26.85, an EV to EBITDA ratio of 58.99, and a low ROE of 4.49%, especially when compared to more favorably rated peers like Cipla and Dr. Reddy's Labs, while also underperforming the Sensex with a year-to-date return of -37.28%.

As of 14 May 2025, the valuation grade for Albert David has moved from attractive to risky, indicating a significant shift in its perceived value. The company is currently overvalued, as evidenced by its high PE ratio of 26.85 and an EV to EBITDA ratio of 58.99, which are considerably above industry norms. Additionally, the ROE stands at a low 4.49%, suggesting inefficiencies in generating returns relative to shareholder equity.<BR><BR>In comparison to its peers, Albert David's valuation metrics appear unfavorable. For instance, Cipla, which is rated as attractive, has a PE ratio of 22.99 and an EV to EBITDA of 15.93, while Dr. Reddy's Labs, also attractive, has a PE of 19.49 and an EV to EBITDA of 12.87. The disparity in these ratios highlights the overvaluation of Albert David relative to its competitors. Furthermore, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -37.28% compared to the Sensex's 5.63%, reinforcing the notion of overvaluation.

Has Albert David declared dividend?

Albert David Ltd has declared a 115% dividend, amounting to 11.5 per share, with an ex-date of August 2, 2024. While recent total returns have been negative over the last 6 months and 1 year, longer-term returns show positive growth.

Albert David Ltd has declared a 115% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 115%<BR>- Amount per share: 11.5<BR>- Ex-date: 02 Aug 24<BR><BR>Dividend Yield: 1.43%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -40.98%, the dividend return was 0%, resulting in a total return of -40.98%.<BR><BR>For the 1-year period, the price return was -25.21%, the dividend return was 0.97%, leading to a total return of -24.24%.<BR><BR>Over the 2-year period, the price return was 34.72%, the dividend return was 3.36%, culminating in a total return of 38.08%.<BR><BR>In the 3-year period, the price return was 49.75%, the dividend return was 5.89%, resulting in a total return of 55.64%.<BR><BR>For the 4-year period, the price return was 71.39%, the dividend return was 7.33%, leading to a total return of 78.72%.<BR><BR>In the 5-year period, the price return was 54.4%, the dividend return was 8.61%, culminating in a total return of 63.01%.<BR><BR>Overall, while Albert David Ltd has declared a significant dividend, the recent total returns over shorter periods indicate a challenging performance, particularly in the last 6 months and 1 year. However, the longer-term returns show a more positive trend, suggesting potential recovery and growth.